SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Advanced Emissions Solutions, Inc. of Class Action Lawsuit and Upcoming Deadline -- ADES

NEW YORK, June 27, 2014 (GLOBE NEWSWIRE) -- Pomerantz LLP has filed a class action lawsuit against Advanced Emissions Solutions, Inc. ("Advanced Emissions" or the "Company") (Nasdaq: ADES ) and certain of its officers. The class action, filed in United States District Court, District of Colorado, and docketed under 1:14-cv-01243, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Advanced Emissions securities between March 14, 2013 and March 12, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Advanced Emissions securities during the Class Period, you have until June 30, 2014 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Advanced Emissions Solutions, Inc., together with its subsidiaries, provides environmental technologies and specialty chemicals to the coal-burning electric power generation industry, primarily in the United States. It operates through three segments: Refined Coal, Emission Control, and CO2 Capture.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, prospects and performance. Specifically, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was employing improper accounting practices, particularly with respect to its method for recognizing revenue for its Emission Control business segment contracts; (ii) the Company was experiencing increased operating losses, primarily driven by a reduction of revenues and margins for its Emission Control segment with a corresponding increase in backlog; (iii) the improper accounting practices would require the Company to restate its reported financial statements, and (iv) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.

On March 13, 2014, the Company announced in a Securities and Exchange Commission ("SEC") Form 8-K filing that, "the Company is currently reviewing its accounting practices, particularly its methods of recognizing revenue for its Emission Control business segment contracts. The Company expects the result of this review will likely result in increased operating losses, primarily driven by a reduction of revenues and margins for its emission control segment with a corresponding increase in backlog for the same period."

On this news, shares of Advanced Emissions fell from $54.23 to $50.90, on March 13, 2014, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com .

Robert S. Willoughby Pomerantz LLP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 356

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 150

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 347

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 238

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Canada Navigates Operational Challenges Amid Storms

Updated Category News Views 205

Air Canada's Operational Challenges and Responses Air Canada has recently faced significant operational hurdles due to severe winter weather and an aircraft incident impacting its Toronto Pearson international hub. These challenges have necessitated a comprehensive update from the airline about its current status and ongoing recovery efforts. Recent Weather Impact on...

Continue Reading
Insight into Melexis' Ongoing Share Buy-Back Strategy

Updated Category News Views 128

Melexis Enhances Shareholder Value Through a Strategic Buyback Melexis, a leader in the semiconductor industry, has been actively engaging in a strategic share buy-back program aimed at bolstering shareholder value. This initiative, first announced on December 10, 2024, reflects the company's commitment to enhancing its stock's performance while also optimizing its...

Continue Reading
Value Line, Inc. Launches New Share Repurchase Initiative

Updated Category News Views 220

Value Line, Inc. Announces Stock Repurchase Program Value Line, Inc. (NASDAQ: VALU) recently revealed an exciting development for its shareholders: the Board of Directors has approved a share repurchase program that allows for the buyback of up to $2,000,000 worth of shares. This program comes into effect immediately and marks a significant move that replaces the previous...

Continue Reading
IsoEnergy Expands Stake in Premier American Uranium Inc. Assets

Updated Category News Views 154

IsoEnergy Enhances Investment in Premier American Uranium Inc. IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) has recently expanded its investment in Premier American Uranium Inc. by acquiring a significant number of common shares and warrants. This strategic move further establishes IsoEnergy’s commitment to capitalizing on the promising uranium market amid increasing...

Continue Reading
Texas Attorney General Takes Action Against Insulin Price Fixing

Updated Category News Views 70

Texas Attorney General's Lawsuit Against Insulin Price Fixing Texas Attorney General Ken Paxton has taken significant action by filing a lawsuit against several prominent insulin manufacturers and pharmacy benefit managers (PBMs). The lawsuit highlights allegations of a conspiracy to inflate insulin prices, affecting countless patients who rely on this vital medication....

Continue Reading